Search

The ROP Network: a south-south collaboration to improve care for premature babies

Retinopathy of prematurity (ROP) is a disorder of the immature preterm retina and a leading cause of preventable, irreversible blindness in children. There are 15 million preterm births annually, and over 32,000 neonates became blind from ROP in 2010 [1]....

100 years of insulin

*Joint first authors The centenary of the discovery of insulin is a time to celebrate one of the most significant scientific discoveries of the 20th century. Background Before 1923, Type 1 diabetes mellitus [T1DM] resulted in death from severe ketoacidosis...

How do you solve the problem of trachoma in Ethiopia?

Background Trachoma is one of the oldest diseases known to humankind and the leading infectious cause of blindness worldwide. Spread by the bacterium chlamydia trachomatis, it is transmitted through contact with the eyes, eyelids and nose of those infected. The...

Primary eye health care in low- and middle-income countries

The need for eyecare services in low- and middle-income countries Recent global estimates (2020) suggest that there is more than a three-fold difference in the prevalence of all categories of visual loss (presenting visual acuity <6/12 in the better eye)...

Quality matters in the management of serious eye disorders

The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD

Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Clinical and management strategies in glaucoma practice: perspectives from international glaucoma specialists

Management options and outcomes in glaucoma practice were reviewed at the 7th Moorfields International Glaucoma Symposium, held in London on 24 January 2015. This article summarises perspectives from international glaucoma specialists on debated issues in topical therapy, glaucoma surgery, diagnostic...

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...